With that as the backdrop, here's a rundown of three monster stocks to buy ... Whereas traditional pharma R&D work might require several years and hundreds of millions of dollars just to complete ...

Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins.

They're not just leaders of their industry. Their underlying businesses are also on the verge of enormous growth.

A number of stocks ... (NASDAQ:OMCL) fell 5.4%. Is now the time to buy Omnicell? Access our full analysis report here, it’s free. Branded Pharmaceuticals company Royalty Pharma (NASDAQ:RPRX ...

NAARDEN, the Netherlands and MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or ... In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib ...

In U.S. premarket trading, stocks of large drugmakers tumbled, with Pfizer (NYSE:PFE) and AbbVie (NYSE:ABBV) falling 3.8% and 5.7%, respectively, Merck & Company Inc (NYSE:MRK) off 4.5%, and Amgen ...

Pharma companies were spared ... intensify selling pressure on biotech stocks. Despite the uncertainty, top hedge fund managers have invested millions of dollars in biotech and pharmaceutical ...

The Nikkei 225 is falling more than 3 percent to below the 32,000 mark, with weakness across all sectors led by technology and financial stocks ... while Sumitomo Pharma and Konica Minolta ...

Stock Market LIVE Updates | Equity benchmark indices Sensex and Nifty rallied on Monday, buoyed by strong buying in ...

For Thursday and Friday, the Dow was down 9.3%, the S&P 500 10.5% and the Nasdaq 11.4% ... This pushed U.S. bank stocks down further, with the sector under pressure globally, as the prospect ...

While the U.S. president's international trade-policy posturing has certainly played a part, growth actually began to lag less-risky investments (like value stocks and dividend payers) late last year.

US drugmakers' shares drop 3% to 6% premarket European, Indian healthcare stocks drag down broader indexes Trump aims to shift pharma manufacturing ... are being pursued under emergency powers ...